North America remains a dominant region in the global patient-derived xenograft model market due to increasing cancer prevalence, growing investments in drug discovery, and the widespread adoption of innovative preclinical research technologies. The region benefits from a well-established healthcare ecosystem, strong regulatory support for biomedical research, and the presence of major contract...